ApoC-III Inhibition in Hypertriglyceridemia: From Triglyceride Lowering to Clinical Risk Modification [0.03%]
高甘油三酯血症中的ApoC-III抑制：从降低甘油三酯到临床风险改良
Attilio Lauretti,Luigi Spadafora,Marco Bernardi et al.
Attilio Lauretti et al.
Ghazal Razeghi,Faisal Ahmed,Alfred E Genadri et al.
Ghazal Razeghi et al.
Background: Corticosteroids are widely used in pericarditis despite guideline recommendations reserving them for select indications. Observational studies have reported inconsistent associations between corticosteroid use...
Safety and Efficacy of Colchicine for the Treatment of Pericarditis in Patients with Chronic Kidney Disease [0.03%]
慢性肾病患者治疗心包炎使用秋水仙碱的安全性和有效性评估研究
Khaznah Saad A Alshammari,Sasha Pierre-Paul,Liriany Pimentel et al.
Khaznah Saad A Alshammari et al.
This retrospective multicenter cohort study compared the safety and efficacy of low- versus high-dose colchicine in adult patients with chronic kidney disease (CKD) treated for pericarditis between August 2015 and August 2024. CKD was ident...
The Subclinical Window for Cardioprotection in Duchenne Muscular Dystrophy: A Systematic Review and Meta-analysis [0.03%]
杜氏肌营养不良心脏保护的亚临床窗口：系统性回顾和meta分析
Feras Shatarat,Amer A Alomari,Osama Bdarnh et al.
Feras Shatarat et al.
Cardiomyopathy is a major cause of morbidity and mortality in Duchenne muscular dystrophy (DMD). Myocardial injury begins during a prolonged subclinical phase while left ventricular ejection fraction (LVEF) remains preserved, suggesting a p...
Incretin-based therapies, alcohol and tobacco use, and acute substance-related events: emerging implications for cardiovascular medicine [0.03%]
基于肠泌素的疗法、酒精和烟草使用以及急性物质相关事件：心血管医学领域的新兴影响
Ovidio De Filippo,Francesco Bruno,Federico Giacobbe et al.
Ovidio De Filippo et al.
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and dual incretin agonists are now familiar drugs in obesity, diabetes, heart failure, and cardiovascular prevention. At the same time, a clinically relevant but molecule-specific human l...
Jacopo D&#x;Andria Ursoleo,Giuseppe Biondi-Zoccai,George W Booz
Jacopo D&#x;Andria Ursoleo
Clopidogrel resistance in ischemic stroke patients: current insights, risk factors, and the role of platelet function testing - a narrative review [0.03%]
缺血性卒中患者氯吡格雷抵抗的现状、危险因素及血小板功能检测的作用：叙事综述
Weihua Li,Yan Zhao,Mengchen Yu et al.
Weihua Li et al.
Clopidogrel, as an antiplatelet drug, is important for the treatment of the secondary prevention of ischemic stroke according to the latest guidelines on ischemic stroke management. However, some patients still fail to achieve a drug respon...
Pharmacologic Management of Type 2 Myocardial Infarction: An Underdefined Frontier [0.03%]
二型心肌梗死的药理学管理：一个尚不明确的领域
Chanokporn Puchongmart,Cristian Castillo Rodriguez,Dina Soliman et al.
Chanokporn Puchongmart et al.
Type 2 myocardial infarction (T2MI) results from myocardial oxygen supply-demand imbalance in the absence of acute atherothrombotic plaque rupture and is associated with substantial short- and long-term mortality. Although increasingly reco...
INTERLEUKIN-1 RECEPTOR ANTAGONIST LEVELS IN PATIENTS WITH HEART FAILURE AND REDUCED EJECTION FRACTION TREATED WITH ANAKINRA [0.03%]
射血分数降低的心力衰竭患者使用阿那白滞素治疗后IL-1受体拮抗剂水平变化
Jazmin Kelly,Eleonora Mezzaroma,Andrea Roscioni et al.
Jazmin Kelly et al.
Patients with heart failure and reduced ejection fraction (HFrEF) commonly show signs of systemic inflammation. Interleukin-1 (IL-1) is a pro-inflammatory cytokine, known to modulate cardiac function. We aimed to determine the effects of tr...